🇺🇸 FDA
Patent

US 8609716

Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof

granted A61PA61P13/00A61P15/08

Quick answer

US patent 8609716 (Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P13/00, A61P15/08, A61P19/08, A61P19/10